A review of the therapeutic management of ulcerative colitis-Reference-Cited by-同舟云学术

A review of the therapeutic management of ulcerative colitis

Published:2022-01 Issue: Volume:15 Page:175628482211381
ISSN:1756-2848
Container-title:Therapeutic Advances in Gastroenterology
language:en
Short-container-title:Therap Adv Gastroenterol

Author:

Aslam Nasar¹,Lo Sheng Wei²,Sikafi Rafid³,Barnes Tom⁴,Segal Jonathan⁵⁶^ORCID,Smith Philip J⁷,Limdi Jimmy K⁸⁹^ORCID

Affiliation:

1. Department of Gastroenterology, University College London Hospitals, 235 Euston Road, London, NW1 2BU, UK

2. Northern Hospital, Epping, VIC, Australia

3. St Mark’s Hospital, London North West University Healthcare NHS Trust, London, UK

4. Section of IBD – Division of Gastroenterology, Northern Care Alliance NHS Foundation Trust, Salford, UK

5. Northern Hospital, Epping, Melbourne, VIC, Australia

6. Department of Medicine, University of Melbourne, Parkville, VIC, Australia

7. Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals Foundation NHS Trust, Liverpool, UK

8. Section of IBD – Division of Gastroenterology, Northern Care Alliance NHS Foundation Trust, Manchester, UK

9. Manchester Academic Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Abstract

Ulcerative colitis (UC) is a chronic relapsing and remitting gastrointestinal disorder of uncertain aetiology. The last two decades have seen an expansion in the therapeutic arsenal used to treat UC. This has resulted in improved clinical remission and response rates. Nonetheless, staples in our current medical management originate from trials conducted in the early 20th century. In this review article, we aim to outline the key milestones in the history of the medical management of UC in addition to highlighting promising therapeutic developments for the future.

Publisher

SAGE Publications

Subject

Gastroenterology

Link

http://journals.sagepub.com/doi/pdf/10.1177/17562848221138160

Reference129 articles.

1. Ulcerative colitis

2. Historical evolution of the management of severe ulcerative colitis

3. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

4. Cortisone in Ulcerative Colitis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Caffeine and naloxone treated mesenchymal stem cells improve symptoms and reduce inflammation in a mouse model of ulcerative colitis;Transplant Immunology;2024-02

2. Anti-oxidant and anti-inflammatory potential of different polymer-based mesalamine delayed-release granules in TNBS-induced ulcerative colitis in wistar rats;Saudi Pharmaceutical Journal;2024-01

3. Dexamethasone restores TNFα-induced epithelial barrier dysfunction in primary rat alveolar epithelial cells;PLOS ONE;2023-12-27

4. Ethyl acetate extract of Terminalia chebula alleviates DSS-induced ulcerative colitis in C57BL/6 mice;Frontiers in Pharmacology;2023-12-12

5. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA;Pharmaceutics;2023-11-11